Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia

Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia

Bibliographic Details
Main Authors: Dennis, Mike, Davies, Michelle, Oliver, Stuart, D’Souza, Roy, Pike, Laura, Stockman, Paul
Format: Online
Language:English
Published: Springer-Verlag 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3428523/
id pubmed-3428523
recordtype oai_dc
spelling pubmed-34285232013-01-02 Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia Dennis, Mike Davies, Michelle Oliver, Stuart D’Souza, Roy Pike, Laura Stockman, Paul Original Article Springer-Verlag 2012-08-04 2012-09 /pmc/articles/PMC3428523/ /pubmed/22864876 http://dx.doi.org/10.1007/s00280-012-1939-2 Text en © The Author(s) 2012
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Dennis, Mike
Davies, Michelle
Oliver, Stuart
D’Souza, Roy
Pike, Laura
Stockman, Paul
spellingShingle Dennis, Mike
Davies, Michelle
Oliver, Stuart
D’Souza, Roy
Pike, Laura
Stockman, Paul
Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
author_facet Dennis, Mike
Davies, Michelle
Oliver, Stuart
D’Souza, Roy
Pike, Laura
Stockman, Paul
author_sort Dennis, Mike
title Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
title_short Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
title_full Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
title_fullStr Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
title_full_unstemmed Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
title_sort phase i study of the aurora b kinase inhibitor barasertib (azd1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
description
publisher Springer-Verlag
publishDate 2012
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3428523/
_version_ 1611552418642788352

Similar Items